Across TCGA pan-cancer cohorts, ZBTB37 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZBTB37 data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ZBTB37 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZBTB37 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, LUAD, and UCEC are the cancer types where ZBTB37 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.120	0.578	.006	22	view →
LUAD	OS	Median	All	0.261	0.837	<.001	8	view →
UCEC	DFS	Median	All	0.961	0.626	.023	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ZBTB37 tumor-vs-normal RNA expression · all ZBTB37 data types